Kymera presents Phase 1 healthy volunteer data for oral STAT6 degrader KT-621

Kymera Therapeutics, Inc.

Hosted conference call on June 2, 2025 to discuss Phase 1 results for KT-621, a first-in-class oral STAT6 degrader.
Slide presentation furnished as Exhibit 99.1; specific safety, PK/PD, or efficacy data not provided in available text.
KT-621 targets immuno-inflammatory diseases; Phase 1 study in healthy volunteers completed.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.